Immuno-oncology spotlight falls on cervical cancer
Formal approval for Keytruda looks to make life difficult for some anti-PD-(L)1 latecomers.
Biggest unpartnered assets: Argenx nears crunch time
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
Covid-19 scrambles big medtech’s spending
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Healthineers scores big in the third quarter
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.
The bubble bursts for biotech stocks
After a frothy couple of years, biotechs are no longer seeing big boosts from clinical data.
Covid-19 takes its toll on medtechs’ efficiency
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.
Covid-19 research efforts slow
A few developers are still finding reasons to research novel pandemic treatments, though much of the ongoing work is focused on proven approaches.
Tecentriq pullout dominates the latest PD-(L)1 moves
July and August saw key regulatory and clinical developments for several anti-PD-(L)1 MAbs, with plenty more in store for oncology watchers.
The sellside’s most controversial products
Drugs prompting the most divergent opinions on outlook include Pfizer and Vir’s Covid-19 offerings and Biogen’s Aduhelm.
